ETANERCEPT

Information current as at: 1 June 2026

The pharmaceutical company has not advised whether they intend to proceed or not within 60 days of receiving the ratified PBAC minutes. The process for listing is considered inactive.

Legend:

Completed N In progress

Not applicable N Yet to commence

Submission Details

Brand name:: Rymti®
Form and strength:: Please search for and view the medicine's Public Summary Document (PSD) for more information
Submission sponsor:: Alphapharm Pty Ltd
Condition/indication: (therapeutic use): Rheumatoid arthritis; Plaque psoriasis; Ankylosing spondylitis; Psoriatic arthritis; Juvenile idiopathic arthritis; Paediatric plaque psoriasis.
Listing requested:: Please see PSD for more information
Funding program:: Please see PSD for more information
Request authority level:: Please see PSD for more information
PBAC Submission type:: New listing (–)
Comment:: --
Other PBAC consideration:: --

Progress Details

Submission received for:: November 2021 PBAC meeting
Opportunity for consumer comment:: Open 28/07/2021 and close 22/09/2021 (see PBS Website)
PBAC meeting:: Held on 03/11/2021
PBAC outcome published:: Recommended (see PBAC Outcomes)
Notice of intent submitted:: Awaiting lodgement from pharmaceutical company
Lodgement of required documentation:: Not applicable
Agreement to listing arrangements:: Not applicable
Government processes:: Not applicable
Medicine listed on the PBS:: Not applicable

Glossary

PBAC Outcome

PBAC Recommendation:

Please see the Outcomes from the relevant meeting for more information

Public Summary Document:

Public Summary Documents – November 2021

Case ID

a407

Page last updated

31 March 2026

Return to the Medicine Status Listing

v.9.19